Long-term study of adding ovarian suppression to tamoxifen in young women
Part of Cancer, Skin clinical trials.
This study is following young women who took part in an earlier trial (ASTRRA) to see if adding ovarian function suppression to tamoxifen helps them over the long term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a premenopausal woman with hormone receptor-positive (HR+) breast cancer.
- You were enrolled in the ASTRRA study between March 1, 2009, and July 17, 2018.
- You have long-term follow-up information available.
- You have not had a hysterectomy or both ovaries removed.
- You have not had another cancer besides breast cancer within the last 5 years.
- You have not had CMF chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching the type of ovarian-suppressing medication helps keep hormone-sensitive breast cancer under control in younger women. You'll be screened to see if your current treatment is working, then potentially switched to a different formulation to see if it works better.
This trial tests if taking hormone therapy for 5 more years helps prevent breast cancer from coming back. It is for women who have already completed 5 years of tamoxifen or an aromatase inhibitor and had lymph node involvement at diagnosis.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.
This trial looks at how a hormone called AMH changes over time in women aged 45-55 with hormone receptor-positive breast cancer who are starting chemotherapy or hormone therapy. The goal is to see if AMH levels can help predict how well their ovaries are still working.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.